Does Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?

Simply Wall St.11-25

Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586420978?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-11-25 16:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586420978","market":"sg","top_or_hot":-1,"title":"Does Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-25 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0634319403.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap","article_id":"2586420978","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586420978","pubTimestamp":1764058503,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's Disease, marking the first such therapy of its kind developed in China for disease modification. \nThis milestone also signifies Akeso's entry into innovative central nervous system therapeutics, leveraging enhanced brain penetration and robust preclinical results for potential next-generation...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK1161":"生物科技","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1574":"生物医药B类股","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","09926":"康方生物","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC"},"translate_title":"康方生物（SEHK：9926）首个阿尔茨海默病双特异性抗体获批是否重塑了其创新叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1.5},"content_text":"Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's Disease, marking the first such therapy of its kind developed in China for disease modification.  This milestone also signifies Akeso's entry into innovative central nervous system therapeutics, leveraging enhanced brain penetration and robust preclinical results for potential next-generation Alzheimer's treatments. With AK152's clinical trial approval as China’s first bispecific antibody for Alzheimer's, we'll examine how it reshapes Akeso's investment narrative. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.AdvertisementAkeso Investment Narrative RecapTo be a shareholder in Akeso, one needs confidence in the company’s ability to turn scientific breakthroughs into commercial success, particularly by expanding its R&D-driven portfolio beyond oncology. The NMPA’s approval of AK152 for Alzheimer’s clinical trials brings much-needed diversification in its pipeline and could emerge as a vital short-term catalyst, even as continued losses and heavy reliance on a few commercialized products remain core risks in the near term. Of Akeso’s recent announcements, the inclusion of ivonescimab and cadonilimab in China’s National Reimbursement Drug List stands out as complementary to the AK152 milestone. This increased market access and anticipated revenue growth help balance the short-term drag on margins from the price cut, supporting the company’s ambitions for profitability and strengthening its financial base for further innovation. Yet, investors should be aware that, in contrast to this expanding R&D portfolio, Akeso’s ongoing challenge is still... Read the full narrative on Akeso (it's free!)Akeso's narrative projects CN¥8.0 billion revenue and CN¥2.0 billion earnings by 2028. This requires 55.4% yearly revenue growth and a CN¥2.51 billion earnings increase from the current CN¥-514.5 million.Uncover how Akeso's forecasts yield a HK$172.00 fair value, a 53% upside to its current price.Exploring Other PerspectivesSEHK:9926 Community Fair Values as at Nov 2025 Retail investors in the Simply Wall St Community assigned Akeso fair value estimates ranging widely from HK$70 to HK$200.74, based on six independent analyses. While these perspectives are diverse, the company’s ongoing reliance on a handful of key therapies for commercial revenue highlights the importance of considering multiple angles on future performance.Explore 6 other fair value estimates on Akeso - why the stock might be worth as much as 78% more than the current price!Build Your Own Akeso NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Akeso research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Akeso research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Akeso's overall financial health at a glance.Contemplating Other Strategies?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Uncover the next big thing with financially sound penny stocks that balance risk and reward.We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586420978","isCrawlerRequest":true}